170 related articles for article (PubMed ID: 31161439)
1. Comments on: High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany.
Cransac A; Aho S; Boulin M
Support Care Cancer; 2020 Jan; 28(1):1-2. PubMed ID: 31161439
[No Abstract] [Full Text] [Related]
2. Response to the letter to the Editor concerning our article "High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany".
Feiten S; Chakupurakal G; Feustel HP; Maasberg M; Otremba B; Ehscheidt P; Hensel M; Hansen R; Weide R
Support Care Cancer; 2020 Jan; 28(1):3-4. PubMed ID: 31701271
[No Abstract] [Full Text] [Related]
3. [IMiDs in hematology].
Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I
Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980
[TBL] [Abstract][Full Text] [Related]
4. High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany.
Feiten S; Chakupurakal G; Feustel HP; Maasberg M; Otremba B; Ehscheidt P; Hensel M; Hansen R; Weide R
Support Care Cancer; 2019 Nov; 27(11):4265-4271. PubMed ID: 30859307
[TBL] [Abstract][Full Text] [Related]
5. Novel immunomodulatory compounds in multiple myeloma.
Saini N; Mahindra A
Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
[TBL] [Abstract][Full Text] [Related]
6. New immunomodulatory drugs in myeloma.
Lacy MQ
Curr Hematol Malig Rep; 2011 Jun; 6(2):120-5. PubMed ID: 21327565
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Raza S; Safyan RA; Lentzsch S
Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.
Madan S; Lacy MQ; Dispenzieri A; Gertz MA; Buadi F; Hayman SR; Detweiler-Short K; Dingli D; Zeldenrust S; Lust J; Greipp PR; Rajkumar SV; Kumar S
Blood; 2011 Aug; 118(7):1763-5. PubMed ID: 21673347
[TBL] [Abstract][Full Text] [Related]
9. [Immunomodulatory drugs (IMiDs)].
Oshima K; Ichinohe T
Nihon Rinsho; 2014 Jun; 72(6):1130-5. PubMed ID: 25016816
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of multiple myeloma with thalidomide and immunomodulatory drugs].
Hattori Y
Nihon Rinsho; 2007 Jan; 65 Suppl 1():596-600. PubMed ID: 17476758
[No Abstract] [Full Text] [Related]
11. Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies.
Chen M; Zhao Y; Xu C; Wang X; Zhang X; Mao B
Ann Hematol; 2018 Jun; 97(6):925-944. PubMed ID: 29500711
[TBL] [Abstract][Full Text] [Related]
12. Second-generation immunomodulatory drugs in leptomeningeal myeloma.
Bohn JP; Willenbacher W; Peschel I; Oberacher H; Steurer M
Leuk Lymphoma; 2019 Feb; 60(2):550-552. PubMed ID: 30032690
[No Abstract] [Full Text] [Related]
13. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Cornell RF; Goldhaber SZ; Engelhardt BG; Moslehi J; Jagasia M; Harrell S; Rubinstein SM; Hall R; Wyatt H; Piazza G
Br J Haematol; 2020 Aug; 190(4):555-561. PubMed ID: 32314352
[TBL] [Abstract][Full Text] [Related]
14. [Thalidomide: mechanisms of action and new insights in hematology].
Leleu X; Micol JB; Guieze R; Berthon C; Kuhnovsky F; Terriou L; Moreau AS; Yakoub-Agha I; Bauters F; Facon T
Rev Med Interne; 2005 Feb; 26(2):119-27. PubMed ID: 15710258
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory drugs in the treatment of multiple myeloma.
Abe Y; Ishida T
Jpn J Clin Oncol; 2019 Aug; 49(8):695-702. PubMed ID: 31187860
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory drugs in multiple myeloma.
Zangari M; Elice F; Tricot G
Expert Opin Investig Drugs; 2005 Nov; 14(11):1411-8. PubMed ID: 16255679
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Anderson KC
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.
Castelli R; Cannavò A; Conforti F; Grava G; Cortelezzi A
Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):740-53. PubMed ID: 22401643
[TBL] [Abstract][Full Text] [Related]
19. The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Pan B; Lentzsch S
Pharmacol Ther; 2012 Oct; 136(1):56-68. PubMed ID: 22796518
[TBL] [Abstract][Full Text] [Related]
20. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
